Decentralized trial tools and technologies are here to stay: A regulatory perspective

Decentralized clinical trial (DCT) strategies and tools such as telehealth visits, centralized monitoring, and remote source data verification (SDV) gained traction overnight during the Coronavirus Disease (COVID-19) pandemic, while already common practices such as direct-to-patient (DTP) drug delivery and home nursing became even more widespread.

Regulators rapidly adjusted the rules on protocol deviations in unprecedented ways to ensure the continuation of clinical research. For example, when the World Health Organization (WHO) declared COVID-19 a global pandemic in March 2020, both the FDA and EMA issued guidance on conducting clinical trials (CTs) that allowed the substitution of remote approaches for on-site activities. In all, dozens of health authorities (HAs) around the world published pandemic rules.

As some countries slowly start to bring the pandemic under control, many companies are wondering whether clinical research will revert to the old ways? The short answer is no.


Open PDF

Return to Insights Center

Related Insights

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Article

Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

Sep 14, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022